Visceral Leishmaniasis and HIV Co-infection in Bihar, India: Long-term Effectiveness and Treatment Outcomes with Liposomal Amphotericin B (AmBisome)
Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease endemic in the Indian state of Bihar, while HIV/AIDS is an emerging disease in this region. A 2011 observational cohort study conducted in Bihar involving 55 VL/HIV co-infected patients treated with 20–25 mg/kg intravenous liposomal amphotericin B (AmBisome) estimated an 85.5% probability of survival and a 26.5% probability of VL relapse within 2 years. Here we report the long-term field outcomes of a larger cohort of co-infected patients treated with this regimen between 2007 and 2012.
Authors: Sakib Burza, Raman Mahajan, Prabhat K. Sinha, Johan van Griensven, Krishna Pandey, Marıa Angeles Lima, Marta Gonzalez Sanz, Temmy Sunyoto, Sunil Kumar, Gaurab Mitra, Ranjeet Kumar, Neena Verma, Pradeep Das
Source: PLOS Neglected Tropical Diseases